NewsAI-assisted

Strand Life Sciences Launches Portal to Help Doctors with Rare Disease Diagnosis; Offers Discounted Testing for Low-Income Patients

Strand Life Sciences launches the StrandOmics Portal, improving rare disease diagnosis with advanced genetic insights.

Simantini Singh Deo
By Simantini Singh Deo
Senior Content Writer
Mar 1, 2025Updated Jun 26, 2025 · 2 min read
Strand Life Sciences Launches Portal to Help Doctors with Rare Disease Diagnosis; Offers Discounted Testing for Low-Income Patients
AI-assisted reporting
Reviewed by Simantini Singh Deo, Senior Content Writer

Bengaluru, February 28, 2025: On the occasion of Rare Disease Day, Strand Life Sciences, a Reliance Industries subsidiary and leading genomics company today launched the StrandOmics Portal to

improve diagnosis of rare diseases.

This new online portal gives clinicians quick and easy access to information on genetic variants, giving them a comprehensive view for each case. This means faster and more accurate diagnosis for patients. In

addition to the portal, Strand Life Sciences will offer rare

disease genetic testing at a reduced cost for patients from economically disadvantaged backgrounds, making these crucial tests more accessible.

The StrandOmics Portal helps doctors by:

  • Providing clear and quick genetic insights for better diagnosis

  • Allowing doctors to independently review a broader set of genetic variants

  • Improving prenatal diagnosis through better collaboration between specialists

    Dr Ramesh Hariharan, CEO & Co-Founder of Strand Life Sciences, said, “We are dedicated to improving genetic diagnostics and making it available to everyone. We will continue to innovate and

    invest in tools like the StrandOmics Portal to empower

    doctors in their fight against rare diseases.”

    About Strand Life Sciences

    Strand Life Sciences, a subsidiary of Reliance Industries Limited, is a genomics-based research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory

    assays and a vast hospital partner network to drive newer

    generations of patient care. Strand’s customers include global medical instruments, diagnostic, and pharmaceutical companies.Strand is also a pioneer of genomic testing in India, and its long global

    bioinformatics track record makes it the most trusted company

    for genomic diagnostics in the areas of oncology, rare diseases, women’s health, and infectious diseases.

    Additionally, Strand is actively expanding into consumer genomics, empowering individuals with personalized insights into their genetic makeup. For more information, visit https://strandls.com

TopicsNews
Simantini Singh Deo
Written by
Simantini Singh Deo
Senior Content Writer

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.

Discussion

Loading discussion…

More from Pharma News

All stories →